An observational study in Bronchopulmonary Dysplasia, sponsored by Konya City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Konya City Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Bronchopulmonary Dysplasia with a site in Turkey — 2 open to participants now, 2 under way, none of them phase 3. Bronchopulmonary Dysplasia · Turkey.
Among the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey, this one is the only one that started in 2026, is one of 5 observational ones, and was the 12th registered.
363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.
Browse Bronchopulmonary Dysplasia studies →2 of the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey are open now. Recruiting first, the newest first:
Kanuni Sultan Suleyman Training and Research Hospital · Sites in Turkey
Ages 1 hrs–6 wk
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 57 Bronchopulmonary Dysplasia studies recruiting now, 6 (11%) set no upper age limit and 50 (88%) stop at 75 or younger; 55 take children under 18; 11 take healthy volunteers.
This study: 0 Days to 28 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is below the median of 150 across 100 observational studies indexed under Bronchopulmonary Dysplasia.
Median enrollment 123 across the 8 interventional studies, 80 across the 5 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Konya City Hospital is the lead sponsor of 82 studies on the registry; 24 are open to participants now.
Konya City Hospital has 1 study filed under Bronchopulmonary Dysplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Bronchopulmonary Dysplasia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07525167Konya City HospitalEarly Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data | 2026-12-01 |
| NCT06940856Kanuni Sultan Suleyman Training and Research HospitalChloride Imbalance in Preterm Infants | 2027-04-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Bronchopulmonary Dysplasia with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data from the First Three Postnatal Weeks with Large Language Models: A Retrospective Study This retrospective, observational study aims to evaluate the early prediction of bronchopulmonary dysplasia (BPD) in preterm infants using clinical data from the first, second, and third postnatal weeks. The study includes infants born before 32 weeks of gestation or weighing less than 1,500 grams, followed at the Neonatal Intensive Care Unit of Konya City Hospital.
The study will compare the performance of different large language models (LLMs), including ChatGPT, Gemini, and Claude, in predicting BPD development. Clinical variables such as gestational age, birth weight, respiratory support, oxygen requirement, mechanical ventilation duration, and infection status will be used.
Primary outcome: Accuracy of BPD risk prediction by each AI model compared to actual clinical outcomes. Secondary outcomes: Sensitivity and specificity of predictions, weekly prediction performance, and comparative performance among AI models.
The results will provide insight into the potential clinical utility of AI-based approaches for early BPD risk assessment in preterm infants.
Premature birth remains a major risk factor for neonatal morbidity and mortality, with bronchopulmonary dysplasia (BPD) representing one of the most significant chronic pulmonary complications in very preterm infants. Despite advances in neonatal intensive care, early and accurate prediction of BPD remains challenging due to the multifactorial nature of its pathophysiology, involving respiratory support requirements, oxygen exposure, infection burden, and perinatal factors.
This retrospective study evaluates the feasibility of using large language models (LLMs) for early prediction of BPD based on structured clinical data extracted from neonatal intensive care unit (NICU) records. Clinical variables are organized into weekly datasets corresponding to the first, second, and third postnatal weeks to capture the dynamic evolution of respiratory status and clinical condition over time.
Standardized and anonymized patient-level datasets are formatted into structured prompts and provided to multiple LLMs (ChatGPT, Gemini, and Claude). Each model receives identical input variables to ensure comparability. The models are instructed to generate categorical risk stratification (low, medium, high) along with corresponding probability estimates for BPD development.
To ensure methodological consistency, prompt engineering is standardized across all models and time points. Outputs are recorded for each weekly time window, allowing temporal comparison of predictive performance and assessment of how early postnatal data influences model accuracy.
Model outputs are subsequently compared with confirmed clinical outcomes of BPD development in the study population. Performance evaluation focuses on discriminative ability and calibration of predictions across different time points and models.
This design enables a systematic assessment of the potential role of LLM-based approaches in neonatal risk stratification and provides insight into their applicability as supportive clinical decision-making tools in neonatal intensive care settings.
A retrospective cohort of preterm infants (\<32 weeks gestation or \<1,500 g) admitted to the NICU of Konya City Hospital. Only infants with complete clinical data and documented BPD status are included. Both sexes are included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This cohort includes preterm infants born before 32 weeks of gestation or weighing less than 1,500 grams, followed at the Neonatal Intensive Care Unit of Konya City Hospital. Clinical data from the first, second, and third postnatal weeks are retrospectively collected for analysis. No interventions are applied; AI models are used to predict BPD risk based on existing clinical data.
Other: Artificial Intelligence-Based Risk Prediction
Different large language models (ChatGPT, Gemini, Claude) will analyze retrospective clinical data to predict the risk of bronchopulmonary dysplasia (BPD). This is an observational evaluation; no experimental treatment or therapy is administered.
Accuracy of bronchopulmonary dysplasia (BPD) risk prediction by artificial intelligence (AI) models in preterm infants.
The primary outcome is the accuracy of different large language models (ChatGPT, Gemini, Claude) in predicting BPD development. AI-generated risk predictions will be compared to actual clinical outcomes to assess prediction correctness.
Time frame: Postnatal weeks 1, 2, and 3
Sensitivity and specificity of AI predictions
Evaluate the true positive rate (sensitivity) and true negative rate (specificity) of each AI model's BPD risk predictions compared to actual outcomes.
Time frame: Postnatal weeks 1, 2, and 3
Comparison of prediction accuracy across postnatal weeks
Compare AI model performance at different postnatal weeks to determine if prediction accuracy improves as more clinical data becomes available.
Time frame: Postnatal weeks 1, 2, and 3
Comparative performance of different AI models
Compare AI model performance at different postnatal weeks to determine if prediction accuracy improves as more clinical data becomes available.
Time frame: Postnatal weeks 1, 2, and 3
Plan to share: No — This study uses retrospective, de-identified clinical data from preterm infants admitted to the Neonatal Intensive Care Unit of Konya City Hospital. All patient information has been anonymized to protect privacy and confidentiality. Due to the sensitive nature of neonatal health data and institutional regulations, individual participant data (IPD) will not be shared with other researchers. The study results will be reported in aggregate form only, ensuring that no identifiable information is disclosed.
Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.
Of 47 non-industry observational studies under Bronchopulmonary Dysplasia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 2 months is below that.
Counting every sponsor, half of 49 studies reached it within 56 months; a quarter within 19 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Konya City Hospital